{
  "id": 4179896,
  "title": "Is Eli Lilly Stock Outperforming the Dow?",
  "url": "https://urgent.news/2026/08/28/is-eli-lilly-stock-outperforming-the-dow",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-28T10:35:27.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/eli-lilly-stock-outperforming-dow-103527018.html"
  },
  "original_language": "en",
  "account": "Eli Lilly and Company, a pharmaceutical giant based in Indianapolis, has shown impressive growth in recent years, outperforming the Dow Jones Industrial Average. With a market capitalization of $1.1 trillion, LLY is classified as a mega-cap stock, reflecting its significant influence in the drug manufacturing sector. Over the past 52 weeks, LLY has surged 60.2%, more than doubling the Dow's gain of 17.6%. Even more notably, LLY has consistently outperformed its peer, Johnson & Johnson, which has only grown 50.3% over the same period. The stock's bullish trajectory was further bolstered by recent acquisitions and collaborations aimed at bolstering its pipeline with high-potential assets, while also protecting its near-term margins. Analysts are highly optimistic about LLY, with a consensus rating of \"Strong Buy\" and a mean price target of $1,335.32, suggesting a 13.5% upside from current levels.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}